GenSight Biologics SA AI Stock Analysis
Want to see FR:SIGHT full AI Analyst Report?
GenSight Biologics SA (SIGHT) AI Stock Analysis
GenSight Biologics SA
(Paris:SIGHT)
The score is driven primarily by weak financial performance (revenue collapse, persistent losses, ongoing cash burn, and negative equity), which materially raises funding and solvency risk. Technicals are more neutral than bearish (RSI near 50 and slightly positive MACD), providing limited support. Valuation remains unattractive/unclear due to negative earnings and no dividend yield.
GenSight Biologics SA (SIGHT) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 18.61M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.46M
- Price to Earnings (P/E)
- -1.0
- Beta (1Y)
- 0.43
- Revenue Growth
- -610.31%
- EPS Growth
- 43.88%
- Country
- France
- Employees
- 18
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
GenSight Biologics SA Business Overview & Revenue Model
Company Description
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous syst...
GenSight Biologics SA Financial Statement Overview
Summary
Financials reflect high risk: revenue collapsed (~99.9% down in 2025 vs. 2024), profitability remains deeply negative, operating cash flow is negative every year (ongoing cash burn), and shareholders’ equity has been negative since 2022. Positives include reduced cash burn in 2025 and lower debt (~€12.9M), but overall solvency and funding dependence remain key concerns.
Income Statement
8Very NegativeBalance Sheet
18Very NegativeCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -903.00K | 1,000 | 2.63M | 1.27M | 2.58M | 5.28M |
| Gross Profit | -903.00K | 1,000 | 2.63M | 3.00M | 2.58M | 5.28M |
| EBITDA | -13.21M | -11.24M | -14.76M | -21.73M | -26.77M | -25.52M |
| Net Income | -15.34M | -12.04M | -14.00M | -26.22M | -27.62M | -28.62M |
Balance Sheet | ||||||
| Total Assets | 6.46M | 8.26M | 10.76M | 9.13M | 25.94M | 56.65M |
| Cash, Cash Equivalents and Short-Term Investments | 1.67M | 2.42M | 2.46M | 2.13M | 10.61M | 44.29M |
| Total Debt | 12.84M | 12.86M | 19.11M | 23.54M | 12.65M | 12.57M |
| Total Liabilities | 40.08M | 33.20M | 37.68M | 39.83M | 41.22M | 40.66M |
| Stockholders Equity | -33.62M | -24.94M | -26.92M | -30.67M | -15.28M | 15.99M |
Cash Flow | ||||||
| Free Cash Flow | -8.50M | -9.38M | -12.94M | -24.67M | -34.01M | -17.17M |
| Operating Cash Flow | -8.22M | -9.38M | -12.94M | -24.66M | -33.75M | -17.14M |
| Investing Cash Flow | 165.00K | 180.00K | 17.00K | 209.00K | 172.00K | -16.00K |
| Financing Cash Flow | 9.58M | 9.14M | 13.54M | 15.86M | 95.00K | 23.74M |
GenSight Biologics SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:SIGHT, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.09, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 46.65 is Neutral, neither overbought nor oversold. The STOCH value of 65.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:SIGHT.
GenSight Biologics SA Peers Comparison
Overall Rating
FR:ALCLS46Neutral
FR:SIGHT46Neutral
FR:TNG45Neutral
FR:ABNX42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | EUR 73.27M | -1.70 | -94.14% | ― | -5.98% | -8.67% | |
| 46Neutral | EUR 18.61M | -1.04 | 52.39% | ― | -610.31% | 43.88% | |
| 45Neutral | EUR 197.86M | -4.25 | -29.36% | ― | 189.81% | 38.50% | |
| 42Neutral | EUR 69.70M | -7.20 | -80.82% | ― | -10.38% | -72.05% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:SIGHT | GenSight Biologics | 0.07 | -0.04 | -31.82% | |
| FR:ALCOX | Nicox SA | 0.28 | -0.02 | -7.54% | |
| FR:TNG | Transgene SA | 0.71 | -0.57 | -44.45% | |
| FR:ALCLS | Cellectis SA | 1.01 | -3.29 | -76.44% | |
| FR:ABNX | ABIONYX Pharma SA | 1.59 | -2.48 | -60.95% |
GenSight Biologics SA Corporate Events
GenSight Biologics Closes EUR 1 Million Capital Raise via Shares and Warrants
GenSight Biologics SA, listed on Euronext Paris under the ticker SIGHT, is a clinical-stage biopharma group developing gene therapies for blinding retinal disorders and central nervous system conditions. It focuses on mitochondrial and optogenetic te...
GenSight’s Optogenetic RP Trial Results Published in NEJM, Underscoring Vision-Restoration Potential
GenSight Biologics and Paris’ 15-20 National Hospital reported that results from the GS030 PIONEER Phase 1/2 trial in late-stage retinitis pigmentosa have been published in The New England Journal of Medicine, marking a high-profile validation of the...
GenSight Bolsters Cash with €1 Million Raise as It Prepares RECOVER Phase III Trial
GenSight Biologics has raised about €1.0 million from existing shareholders Heights Capital and Invus through a combined share and warrant issuance, mirroring a prior March 2026 structure. The funds will support operating activities and working capit...
GenSight Biologics Warns on Going-Concern as Exceptional Access Cash Buoys Operations
GenSight Biologics reported cash and cash equivalents of €0.7 million at 30 September 2026, down from €1.7 million at the end of June, despite cumulative gross inflows of €8.2 million from paid exceptional access programs since March. These programs,...
GenSight Boosts Cash Through Early Access as LUMEVOQ Manufacturing Transfer Completes
GenSight Biologics reported that while IFRS revenue for the first half of 2026 came in at a negative €1.2 million due to accrued rebates and a non-cash accounting change, the company collected €6.5 million from paid early access programs, sharply red...
GenSight Biologics Advances GS010 Manufacturing and Early Access Programs Ahead of H1 2026 Results
GenSight Biologics, a clinical-stage gene therapy company focused on retinal and central nervous system disorders, is advancing a pipeline aimed at restoring vision in patients with rare, blinding diseases. Its lead candidate GS010 for Leber Heredita...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026
